Condition: Pregnancy Related · Atopic Dermatitis · Sponsor: Incyte Corporation
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
This description comes directly from the study's public registry record.
Syneos Health · 1.833.917.8791 · opzeluracreampregnancyregistry@syneoshealth.com
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Syneos Health (remote site) | Morrisville, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06259669